Soleno Therapeutics, a Neurocrine Biosciences company, develops therapies for rare genetic disorders. The first and only therapy for the treatment of hyperphagia in #PraderWilliSyndrome received full FDA-approval in March 2025.
C-US-PWS-00066
Shared 1 year ago
7K views
Shared 1 year ago
244 views
Shared 1 year ago
92 views
Shared 1 year ago
164 views
Shared 1 year ago
4.7K views
Shared 2 years ago
441 views
Shared 2 years ago
287 views
Shared 2 years ago
3.8K views
Shared 2 years ago
305 views
Shared 2 years ago
849 views
Shared 2 years ago
284 views